Archamps, June 29th, 2022 – Cathay Capital announced its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic, and financial support to accelerate its growth and global expansion.
Founded in 2012 and based in Archamps (Haute-Savoie, France), TransCure bioServices is a leading “one-stop-shop” preclinical contract research organization (CRO) specialized in advanced preclinical in vivo pharmacology, with mouse models of fully reconstituted human immune system (HIS) or human-liver (Hu-liver) addressing various therapeutic areas including immuno-oncology, infectious diseases and inflammatory auto-immune diseases.
Read the full press release “TransCure bioServices welcomes Cathay Capital to accelerate its ambitious growth”: